Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment

Hypertension Research

Volumn 36, Issue 9, 2013, Pages 753-758

  Yagi, Shusuke ^a   Akaike, Masashi ^b   Ise, Takayuki ^a   Ueda, Yuka ^a   Iwase, Takashi ^a   Sata, Masataka ^a  

^a TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

blood brain barrier; cognitive impairment; RAAS inhibitors

Indexed keywords

ACETYLCHOLINE; ALACEPRIL; ALISKIREN; AZILSARTAN; BENAZEPRIL; CANDESARTAN; CILAZAPRIL; DELAPRIL; ENALAPRIL; EPLERENONE; IMIDAPRIL; INDAPAMIDE; IRBESARTAN; LOSARTAN; NITRENDIPINE; OLMESARTAN; PERINDOPRIL; QUINAPRIL; SPIRONOLACTONE; SUBSTANCE P; TAU PROTEIN; TELMISARTAN; TEMOCAPRIL; TRANDOLAPRIL; VALSARTAN;

ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRAIN CIRCULATION; BRAIN PROTECTION; BRAIN WEIGHT; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; HIPPOCAMPUS; HUMAN; HYPERTENSION; LONG TERM POTENTIATION; MENTAL STRESS; META ANALYSIS (TOPIC); MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEDENTARY LIFESTYLE; SYSTOLIC BLOOD PRESSURE; WORKING MEMORY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COGNITION; COGNITION DISORDERS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84883885656     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.51     Document Type: Review

References (93)

1. Hoshide S, Ishikawa J, Eguchi K, Oowada T, Shimada K, Kario K. Cognitive dysfunction and physical disability are associated with mortality in extremely elderly patients. Hypertens Res 2008; 31: 1331-1338.
2. Uzun S, Kozumplik O, Folnegovic-Smalc V. Alzheimer's dementia: current data review. Coll Antropol 2011; 35: 1333-1337.
3. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood-pressure levels and late-life cognitive function-the Honolulu-Asia Aging Study. JAMA 1995; 274: 1846-1851. (Pubitemid 26001260)
4. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145. (Pubitemid 126512042)
5. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K, Sueishi K, Tsuneyoshi M, Fujishima M. Incidence and risk-factors of vascular dementia and Alzheimers-disease in a defined elderly Japanese population-the Hisayama Study. Neurology 1995; 45: 1161-1168.
6. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62: 1148-1155. (Pubitemid 38456510)
7. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817. (Pubitemid 27111317)
8. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005; 57: 789-794. (Pubitemid 40798616)
9. Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO. Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology 1988; 38: 931-937.
10. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000; 21: 57-62. (Pubitemid 30224786)
11. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451. (Pubitemid 32575406)
12. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
13. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556-1560. (Pubitemid 41434560)
14. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002; 58: 1175-1181. (Pubitemid 34411860)
15. Starr JM, Whalley LJ, Inch S, Shering PA. Blood pressure and cognitive function in healthy old people. J Am Geriatr Soc 1993; 41: 753-756. (Pubitemid 23199016)
16. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Pyorala K, Riekkinen P, Laakso M. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 1993; 22: 771-779. (Pubitemid 23326225)
17. Suhr JA, Stewart JC, France CR. The relationship between blood pressure and cognitive performance in the third national health and nutrition examination survey (NHANES III). Psychosom Med 2004; 66: 291-297. (Pubitemid 38668395)
18. Robbins MA, Elias MF, Elias PK, Budge MM. Blood pressure and cognitive function in an African-American and a Caucasian-American sample: the Maine-Syracuse Study. Psychosom Med 2005; 67: 707-714. (Pubitemid 41396016)
19. Obisesan TO, Obisesan OA, Martins S, Alamgir L, Bond V, Maxwell C, Gillum RF. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2008; 56: 501-509. (Pubitemid 351327944)
20. Cacciatore F, Abete P, Ferrara N, Paolisso G, Amato L, Canonico S, Maggi S, Rengo F. The role of blood pressure in cognitive impairment in an elderly population. J Hypertens 1997; 15: 135-142. (Pubitemid 27118588)
21. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment-A 20-year follow-up of 999 men. Hypertension 1998; 31: 780-786. (Pubitemid 28108576)
22. Elias PK, Elias MF, Robbins MA, Budge MM. Blood pressure-related cognitive decline-Does age make a difference? Hypertension 2004; 44: 631-636. (Pubitemid 39435231)
23. Guo ZC, Fratiglioni L, Winblad B, Viitanen M. Blood pressure and performance on the Mini-Mental State Examination in the very old-Cross-sectional and longitudinal data from the Kungsholmen Project. Am J Epidemiol 1997; 145: 1106-1113. (Pubitemid 27272940)
24. Waldstein SR, Giggey PP, Thayer JF, Zonderman AB. Nonlinear relations of blood pressure to cognitive function-The Baltimore Longitudinal Study of Aging. Hypertension 2005; 45: 374-379. (Pubitemid 40315806)
25. Nagai M, Hoshide S, Kario K. Hypertension and Dementia. Am J Hypertens 2010; 23: 116-124.
26. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. BMJ 1996; 312: 801-805. (Pubitemid 26099297)
27. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, Greenlick MR, Hadley E, Moye L, Perry HM Jr et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994; 154: 2154-2160. (Pubitemid 24317261)
28. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351. (Pubitemid 28510916)
29. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-689.
30. O'Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, Marzona I, Bosch J, Probstfield J, Yusuf S. Cognitive impairment and risk of cardiovascular events and mortality. Eur Heart J 2012; 33: 1777-1786.
31. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-1075. (Pubitemid 36548935)
32. Inaba S, Iwai M, Furuno M, Tomono Y, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Continuous activation of renin-angiotensin system impairs cognitive function in human renin/angiotensinogen transgenic mice. Hypertension 2008; 52: E108-E109.
33. Lenkei Z, Corvol P, Llorenscortes C. The angiotensin receptor subtype At1a predominates in rat forebrain areas involved in blood-pressure, body-fluid homeostasis and neuroendocrine control. Brain Res Mol Brain Res 1995; 30: 53-60.
34. Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pep 1998; 78: 1-11. (Pubitemid 28561511)
35. Veerasingham SJ, Raizada MK. Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br J Pharmacol 2003; 139: 191-202. (Pubitemid 36760351)
36. Johnson ML, Parikh N, Kunik ME, Schulz PE, Patel JG, Chen H, Aparasu RR, Morgan RO. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement 2012; 8: 437-444.
37. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-2052. (Pubitemid 35168212)
38. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-1325. (Pubitemid 39350046)
39. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, Sasaki H. Angiotensinconverting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-650. (Pubitemid 38480653)
40. Rozzini L, Chilovi BV, Bertoletti E, Conti M, Del Rio I, Trabucchi M, Padovani A. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2006; 21: 550-555. (Pubitemid 44043756)
41. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, Investigators H. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699-702. (Pubitemid 34259143)
42. Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Abeta clearance by transplanted adult astrocytes. Glia 2011; 59: 1643-1657.
43. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, Sueta D, Koibuchi N, Yamamoto E, Ogawa H, Kim-Mitsuyama S. Perindopril, a centrally active angiotensinconverting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J 2011; 25: 2911-2920.
44. Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurologica Belgica 2009; 109: 171-180.
45. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurology 2007; 6: 373-378. (Pubitemid 46389616)
46. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J MolMed (Berl) 2008; 86: 715-722.
47. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, Kano M, Ogihara T, Rakugi H, Morishita R. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-U1125.
48. Wang J, Ho L, Chen LH, Zhao Z, Zhao W, Qian XJ, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402. (Pubitemid 350096995)
49. Hajjar I, Brown L, Mack WJ, Chui H. Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012: 1-7.
50. Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, Sedefdjian A, Sevenier F, Shlyakhto EV, Pathak A. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens 2008; 26: 1642-1650.
51. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006; 20: 177-185.
52. Mogi M, Li JM, Iwanami J, Min LJ, Tsukuda K, Iwai M, Horiuchi M. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141-148. (Pubitemid 44297536)
53. Jing F, Mogi M, Sakata A, Iwanami J, Tsukuda K, Ohshima K, Min LJ, Steckelings UM, Unger T, Dahlof B, Horiuchi M. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab 2012; 32: 248-255.
54. von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 2006; 326: 599-616. (Pubitemid 44435828)
55. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172.
56. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995; 18: 370-373.
57. MacLeod AB, Vasdev S, Smeda JS. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke 1997; 28: 1821-1828; discussion 1829.
58. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001; 12: 308-314. (Pubitemid 33714222)
59. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 2001; 281: R944-R950.
60. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63: 686-692.
61. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M, Horiuchi M. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 2007; 566: 153-159. (Pubitemid 46782806)
62. Yagi S, Akaike M, Aihara K, Iwase T, Yoshida S, Sumitomo-Ueda Y, Ikeda Y, Ishikawa K, Matsumoto T, Sata M. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res 2011; 34: 74-78.
63. Sakata A, Mogi M, Iwanami J, Tsukuda K, Min LJ, Jing F, Ohshima K, Ito M, Horiuchi M. Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone. J Renin Angiotensin Aldosterone Syst 2012; 13: 84-90.
64. Ito S, Komatsu K, Yajima Y, Hirayama A. Resin-angiotensin system in the brain as a new target of antihypertensive therapy. Hypertens Res 2008; 31: 1487-1488.
65. Dong YF, Kataoka K, Toyama K, Sueta D, Koibuchi N, Yamamoto E, Yata K, Tomimoto H, Ogawa H, Kim-Mitsuyama S. Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension 2011; 58: 635-642.
66. Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr Med Res Opin 2003; 19: 449-451. (Pubitemid 36994451)
67. Kim-Mitsuyama S, Yamamoto E, Tanaka T, Zhan Y, Izumi Y, Izumiya Y, Ioroi T, Wanibuchi H, Iwao H. Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. Stroke 2005; 36: 1083-1088.
68. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886. (Pubitemid 36677151)
69. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005; 18: 1052-1059. (Pubitemid 41139903)
70. Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 2008; 70 (19 Pt 2), 1858-1866. (Pubitemid 351653953)
71. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59: 863-868. (Pubitemid 38333676)
72. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298: 62-70. (Pubitemid 32574511)
73. Noda A, Fushiki H, Murakami Y, Sasaki H, Miyoshi S, Kakuta H, Nishimura S. Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques. Nucl Med Biol 2012; 39: 1232-1235.
74. Kishi T, Hirooka Y, Sunagawa K. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin- related kinase B in hippocampus of hypertensive rats. J Cardiol 2012; 60: 489-494.
75. Min LJ, Mogi M, Shudou M, Jing F, Tsukuda K, Ohshima K, Iwanami J, Horiuchi M. Peroxisome proliferator-activated receptor-gamma activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012; 59: 1079-1088.
76. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 2012; 12: 207-214.
77. Matsumoto S, Shimodozono M, Miyata R, Kawahira K. Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients. Brain Inj 2009; 23: 1065-1072.
78. Bui JD, Kimura B, Phillips MI. Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier. Eur J Pharmacol 1992; 219: 147-151.
79. Marshall FH, Clark SA, Michel AD, Barnes JC. Binding of angiotensin antagonists to rat liver and brain membranes measured ex vivo. Br J Pharmacol 1993; 109: 760-764. (Pubitemid 23181058)
80. Raghavendra V, Chopra K, Kulkarni SK. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 2001; 35: 65-69. (Pubitemid 32382318)
81. Kjeldsen SE, Lyle PA, Kizer JR, Dahlof B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J Clin Hypertens (Greenwich) 2005; 7: 152-158.
82. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009; 169: 1195-1202.
83. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003; 17: 781-785. (Pubitemid 37441435)
84. Polidori C, Ciccocioppo R, Nisato D, Cazaubon C, Massi M. Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment. Eur J Pharmacol 1998; 352: 15-21. (Pubitemid 28359402)
85. Tan J, Wang JM, Leenen FH. Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats. Am J Hypertens 2005; 18 (2 Pt 1), 158-164. (Pubitemid 40332543)
86. Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol 2003; 14: 323-343. (Pubitemid 38679252)
87. Yamada K, Horita T, Takayama M, Takahashi S, Takaba K, Nagata Y, Suzuki N, Kanda T. Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res1421: 110-120.
88. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe PG, Imbimbo BP, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Pilotto A, Panza F. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordr) 2013; 35: 441-453.
89. Zuccala G, Onder G, Marzetti E, Lo Monaco MR, Cesari M, Cocchi A, Carbonin P, Bernabei R, Grp GS. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005; 26: 226-233. (Pubitemid 40222360)
90. Yabuuchi F, Takahashi M, Aritake K, Fujimoto M, Ito H, Tsuzaki M, Akai T, Yamaguchi M, Hayashi S, Nishino Y, Brautigam M. Post-stroke treatment with imidapril reduces learning deficits with less formation of brain oedema in a stroke-prone substrain of spontaneously hypertensive rats. Fundam Clin Pharmacol 1999; 13: 475-483. (Pubitemid 32250272)
91. Leonetti G, Salvetti A. Effects of cilazapril and nitrendipine on blood pressure, mood, sleep, and cognitive function in elderly hypertensive patients: an Italian multicenter study. J Cardiovasc Pharmacol 1994; 24(Suppl3): S73-S77. (Pubitemid 24361313)
92. Starchina YA, Parfenov VA, Chazova IE, Sinitsyn VE, Pustovitova TS, Kolos IP, Ustyuzhanin DV. Cognitive function and the emotional state of stroke patients on antihypertensive therapy. Neurosci Behav Physiol 2007; 37: 13-17. (Pubitemid 44963714)
93. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M, Horiuchi M. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 2007; 566: 153-159. (Pubitemid 46782806)